In this full-length interview, Thomas (Tom) Metz, a Laboratory Fellow and Chief Science Officer of the Biological Sciences Division at Pacific Northwest National Laboratory, discusses his research and his thoughts from the American Academy of Forensic Sciences (AAFS) Conference.
During the course of the American Academy of Forensic Sciences (AAFS) Conference, which took place from February 17th–22nd, 2025, several important talks took place about the state of the forensic science industry (1). With talks organized by specific topic areas, conference attendees had the chance to attend sessions that directly correlate to their topic of research or what they are interested in. Most of these talks highlighted how forensic science technology is leading to discoveries and changing the way investigations are conducted (1).
One topic area that featured numerous important talks was “Criminalistics.” In this topic area, Metz discussed reference-free identification of fentanyl analogs. Metz’s research focuses on high-throughput metabolomics and lipidomics, integrating proteomics to study chronic and infectious diseases, leading to over 200 publications (2). His recent work has investigated multi-dimensional mass spectrometry (MS) and computational prediction for reference-free compound identification. He previously led metabolomics and proteomics initiatives for major NIH-funded programs (2). From 2021–2023, he served as President of the Metabolomics Association of North America (2). Currently, he leads the PNNL m/q Initiative and co-leads the ChemBio Analytical Sciences Hub of NEXUS for Exposome Research Coordination (2). His expertise advances analytical sciences, enhancing molecular identification and biomarker discovery for disease and environmental studies.
Our full-length interview with Metz covers a wide variety of topics. In our conversation, we discuss his observations on the ground at the American Academy of Forensic Sciences (AAFS) conference. We also dive into his talk, “Reference-Free Identification of Fentanyl Analogs” which he discussed at AAFS. Other topics that were discussed were Metz’s work in using, developing, and applying high throughput metabolomics and lipidomics methods, in conjunction with proteomics, in studies of chronic and infectious diseases, the biggest challenges forensic scientists face, and some of the developments in technology that are impacting this space.
To view more of our coverage of the AAFS Conference, click here.
How Do We Improve Elemental Impurity Analysis in Pharmaceutical Quality Control?
May 16th 2025In this final part of our conversation with Harrington and Seibert, they discuss the main challenges that they encountered in their study and how we can improve elemental impurity analysis in pharmaceutical quality control.
How do Pharmaceutical Laboratories Approach Elemental Impurity Analysis?
May 14th 2025Spectroscopy sat down with James Harrington of Research Triangle Institute (RTI International) in Research Triangle Park, North Carolina, who was the lead author of this study, as well as coauthor Donna Seibert of Kalamazoo, Michigan. In Part I of our conversation with Harrington and Seibert, they discuss the impact of ICH Q3D and United States Pharmacopeia (USP) <232>/<233> guidelines on elemental impurity analysis and how they designed their study.
The Role of LIBS in ChemCam and SuperCam: An Interview with Kelsey Williams, Part III
May 2nd 2025In this extended Q&A interview, we sit down with Kelsey Williams, a postdoctoral researcher at Los Alamos National Laboratory (LANL), who is working on planetary instrumentation using spectroscopic techniques such as laser-induced breakdown spectroscopy (LIBS) and laser ablation molecular isotopic spectrometry (LAMIS). In Part III, Williams goes into detail about ChemCam and SuperCam and how LIBS is used in both these instruments.